Defence Therapeutics Inc.

Defence Therapeutics Inc.

DTCFF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$13.25M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Defence Therapeutics Inc.Defence Therapeutics Inc.-2.6--189%-0.5
$0.00

Current Fair Value

99% downside

Overvalued by 99% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$13.25 Million
Enterprise Value$13.09 Million
Earnings per Share$-0.1
Beta1.35
Outstanding Shares75,788,153

Return

Return on Equity-189.02%ROE
Return on Assets-101.95%
Return on Invested Capital-122.85%

Valuation & Multiples

P/E Ratio-2.63P/E Ratio
PEG-10.4PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-2.04
Enterprise Value to Net Income-2
Total Debt to Enterprise0.13
Debt to Equity0.49Debt to Equity

Revenue Sources

No data

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Defence Therapeutics Inc.

5 employees
CEO: Amie Phinney

Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerst...